<bill session="103" type="s" number="821" updated="2012-07-17T06:16:38-04:00">
	<state datetime="1993-04-22">REFERRED</state>
	<status><introduced datetime="1993-04-22"/></status>

	<introduced datetime="1993-04-22"/>
	<titles>
		<title type="short" as="introduced">Medicare Cancer Coverage Improvement Act of 1993</title>
		<title type="official" as="introduced">A bill to amend title XVIII of the Social Security Act to provide for uniform coverage of anticancer drugs under the Medicare program, and for other purposes.</title>
	</titles>
	<sponsor id="300084"/>
	<cosponsors>
		<cosponsor id="404598" joined="1993-04-27"/>
		<cosponsor id="402412" joined="1993-07-22"/>
		<cosponsor id="409225" joined="1993-06-16"/>
		<cosponsor id="300053" joined="1993-08-05"/>
	</cosponsors>
	<actions>
		<action datetime="1993-04-22" state="INTRODUCED"><text>Sponsor introductory remarks on measure. (CR S4857-4859)</text></action>
		<action datetime="1993-04-22" state="REFERRED"><text>Read twice and referred to the Committee on Finance.</text></action>
	</actions>
	<committees>
		<committee code="SSFI" name="Senate Finance" activity="Referral, In Committee" />
	</committees>
	<relatedbills>

	</relatedbills>
	<subjects>
		<term name="Social welfare"/>
		<term name="Cancer"/>
		<term name="Cancer research"/>
		<term name="Chemotherapy"/>
		<term name="Clinical trials"/>
		<term name="Congressional reporting requirements"/>
		<term name="Drugs"/>
		<term name="Health"/>
		<term name="Medicare"/>
		<term name="Pharmaceutical research"/>
	</subjects>
	<amendments>

	</amendments>
	<summary>
	4/22/1993--Introduced.
Medicare Cancer Coverage Improvement Act of 1993 - Amends title XVIII (Medicare) of the Social Security Act to cover: (1) any use of a drug approved by the Food and Drug Administration in an anticancer chemotherapeutic regimen if such use has been published in select peer-review medical literature or included in one or more of three specified medical compendia; and (2) an oral form of a drug prescribed for anticancer use for a given indication if the drug contains the same active ingredients and indication as a drug that would be covered if administered as incident to a physician's service if the drug could not be self-administered. Requires a study and report to specified congressional committees by the Secretary of Health and Human Services on Medicare coverage of patient care costs associated with clinical trials of new cancer therapies.

	</summary>
</bill>
